The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Zinacef 250 mg Powder for Solution or Suspension for Injection



GlaxoSmithKline (Ireland) LimitedPA1077/014/001

Main Information

Trade NameZinacef 250 mg Powder for Solution or Suspension for Injection
Active SubstancesCefuroxime sodium
Dosage FormPowder for solution for injection
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberPA1077/014/001

Group Information

ATC CodeJ01DC Second-generation cephalosporins
J01DC02 cefuroxime

Status

License statusAuthorised
Licence Issued21/08/1978
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back